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Abstract: Polycystic ovary syndrome (PCOS) is a common endocrinopathy among women associated
with reproductive, metabolic and psychological features. While weight management is recommended
as first-line treatment, it is unclear if women with PCOS achieve similar benefits as women without
PCOS. This systematic review thus aimed to compare the efficacy of weight management interventions
in women with and without PCOS. Databases were searched until May 2017. The primary outcome
was weight and anthropometric, reproductive, metabolic and psychological measures were secondary
outcomes. Of 3264 articles identified, 14 studies involving n = 933 (n = 9 high and n = 5 moderate
risk of bias) met the inclusion criteria. No statistically significant differences in weight or weight loss
following the intervention were found between women with and without PCOS in five studies, with
the remaining studies not comparing the difference in weight or weight loss between these groups.
Secondary outcomes did not differ significantly between the two groups. This review identified that
there is a paucity of high quality research in this area and that more rigorous research is needed.
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1. Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women
of reproductive age, with a prevalence of 6–18%, depending on the diagnostic criteria used
and the population studied [1–3]. The condition is underpinned by insulin resistance (IR) and
hyperandrogenism. These hormonal abnormalities both contribute to clinical features including
hirsutism or acne, oligo-/anovulation and polycystic ovarian morphology, type 2 diabetes (DM2),
metabolic syndrome and cardiovascular disease [4–7]. PCOS also accounts for the majority of cases of
anovulatory infertility [8], and women with PCOS have an increased risk of pregnancy and neonatal
complications [9]. Women with PCOS also have a higher risk of psychological complications, including
depression and anxiety [10].
The etiology of PCOS is complex and poorly understood. Both genetic and environment factors
contribute to the syndrome [11], and both gonadotropin hypersecretion and IR increase androgen
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secretion [12–14]. Women with PCOS appear to have a higher rate of weight gain and a higher
prevalence of overweight, obesity and central obesity, compared to women without PCOS [15–17].
Obesity, especially central obesity, worsens the clinical and biochemical presentation of the
syndrome, contributing to IR, hyperandrogenism, reproductive disorders, diabetes and cardiovascular
disease [18–20]. Weight loss, in turn, improves all the features of PCOS, and lifestyle (diet, physical
activity and behavior) changes and weight management are recommended as first line treatment for
PCOS [21,22] to improve hormonal disturbances and to prevent future reproductive and metabolic
complications. Preconception lifestyle interventions and weight loss are also recommended before
infertility treatment is initiated [23], and lead to higher ovulation rates compared to oral contraceptive
pretreatment [24].
It has been proposed that weight management interventions may be less effective in women
with PCOS compared to those without PCOS given the higher rate of longitudinal weight gain in
PCOS [17]. This may be related to the hormonal aberrations of PCOS such as hyperandrogenemia or
IR, contributing to abnormalities in energy homeostasis and dietary intake including gut hormone
regulation [25,26], or an altered metabolism due to reduced postprandial thermogenesis [27]. However,
the literature is limited and contradictory. The aim of this systematic review is thus to assess the
effect of lifestyle (dietary and non-dietary) weight management interventions on anthropometric,
reproductive and metabolic outcomes in women with PCOS, compared to women without PCOS.
2. Materials and Methods
2.1. Selection Criteria
This systematic review was conducted in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) Statement checklist [28]. The detailed PICO
(Population, Intervention, Comparison, Outcome) framework in Supplementary Table S1, established a
priori, was used to include and exclude articles for this systematic review. Briefly, articles were
included if they reported a study that compared women with PCOS to women without PCOS;
following a weight management intervention; and investigated anthropometric, fertility, reproductive
non-fertility, metabolic, quality of life or emotional wellbeing outcomes. The primary outcome was
weight management defined as either weight loss, weight maintenance or prevention of weight
gain. Secondary anthropometric, reproductive, metabolic and psychological outcomes are listed in
Table S1 and were analysed based on the most complete data, which were body mass index (BMI),
waist circumference for fat distribution, computed tomography for fat and lean mass, number of
ovulations, total testosterone, sex hormone-binding globulin (SHBG), free androgen index (FAI),
fasting glucose, oral glucose tolerance test (OGTT), fasting insulin, total, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) cholesterol, triglycerides, and blood pressure.
2.2. Systematic Search for Evidence
A systematic search (Supplementary Table S2) was developed incorporating terms related to
weight management (including lifestyle, behaviour, pharmacological, surgical and complementary
and alternative interventions) and combined with terms related to PCOS. The search strategy was
limited to English language articles and there were no limits on year of publication. The following
electronic databases were searched via the OVID platform to identify relevant literature up to May
2017: Ovid MEDLINE(R) 1946 to Present with Daily Update; Ovid MEDLINE(R) In-Process and
Other Non-Indexed Citations; Evidence-Based Medicine (EBM) Reviews incorporating Cochrane
Database of Systematic Reviews, EBM Reviews—ACP Journal Club, EBM Reviews—Database of
Abstracts of Reviews of Effects, EBM Reviews—Cochrane Central Register of Controlled Trials, EBM
Reviews—Cochrane Methodology Register, EBM Reviews—Health Technology Assessment, EBM
Reviews—National Health Service (NHS) Economic Evaluation Database; PsycINFO; and EMBASE.
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CINAHL Plus was searched separately on the same date. Bibliographies of relevant articles were also
searched for identification of additional studies.
2.3. Inclusion of Studies
To determine the literature to be assessed further, one trained reviewer (J.K. for search to
23 September 2015 and E.C.T for search to 11 May 2017) screened the titles, abstract sections and
keywords of every article retrieved by the search strategy using the selection criteria described in
Table S1. Full articles were retrieved for further assessment if the information given suggested that
the article met the selection criteria, or if it was unclear. Three additional reviewers were consulted
throughout the screening process.
2.4. Quality Appraisal of the Evidence
Methodological quality, in terms of risk of bias, of the included studies was assessed by two
reviewers (J.K. and E.C.T.) in consultation with experienced reviewers (M.M. and L.J.M.) using criteria
developed a priori [29], designed for cohort studies. Individual quality items were investigated
using a descriptive component approach that assessed selection bias, performance bias, attrition bias,
reporting bias, potential confounding, and appropriateness of statistical analysis. Any disagreement
or uncertainty was resolved by discussion among authors to reach a consensus. Using this approach,
each study was allocated a risk of bias rating. Where there was more than one article describing a
study, all articles were used to complete one risk of bias assessment on the study.
2.5. Data Extraction
Double data extraction, according to the selection criteria described in Table S1 was conducted by
two independent reviewers for the original search (J.K. and A.J.) and by two independent reviewers for
the updated search (A.J. and E.C.T.). Information was collected on relevant outcome data and included
point estimates, measures of variability and number of participants. Where there was more than one
article describing a study, data from the most current and comprehensive article was extracted, and
any additional outcome data reported in additional articles were subsequently extracted.
2.6. Data Synthesis
Due to the heterogeneity in interventions, a meta-analysis was not performed, results are thus
presented narratively and in tabular form. Publication bias could not be assessed due to the lack of
meta-analysis as this requires a meta-analysis to be performed on 10 or more studies. All studies
reported baseline and endpoint values, except for two studies that reported the difference from baseline
to post-intervention. Outcome data has been excluded in instances where only the mean was presented
with no corresponding variance data (standard deviation (SD), standard error (SE), or confidence
interval (CI)). Where necessary, unit conversions were performed so that results are presented in SI
units; in some instances, where conversion factors could not be obtained, the unit from the original
manuscript has been retained.
3. Results
The search returned 3264 articles (Figure 1). Fifty-nine full text articles were retrieved for further
evaluation and 17 articles [30–46] reporting 14 studies met the inclusion criteria. Of these 17 articles,
one study was reported across two articles [31,32] and one study [35] reported data across different
time points [36,37]. Two studies reported data from two intervention groups, respectively [38,39].
A table of studies, excluded based on full text, is found in Supplementary Table S3: Table of Excluded
Studies. All between group comparisons presented here are presented as the authors reported that
data and is per protocol for all analyses.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram. 
3.1. Characteristics and Quality of Included Studies 
The characteristics of included studies are reported in Table 1. All studies were 
comparative/parallel design. Two were designed as randomized controlled studies (RCTs) but 
comprised two intervention groups, respectively, and were used as comparative studies [38,39]. Five 
studies had a moderate risk of bias, whilst nine studies had a high risk of bias (Supplementary Table 
S4). Interventions varied across the included studies (diet, diet + behavior change program, diet + 
Metformin, diet + anti-obesity drug, anti-obesity drug, diet + anti-obesity drug + exercise, bariatric 
surgery, and various exercise training programs), as did the duration of interventions. Nine studies 
were designed with the specific aim of weight loss [34,37–39,41–43,45,46], while the remaining five 
studies did not state if the aim was weight loss [30,31,33,40,44]. The sample size of the studies varied 
from 31 to 1016.  
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram.
3.1. Characteristics and Quality of Included Studies
The characteristics of included studies are reported in Table 1. All studies were
comparative/parallel design. Two were designed as randomized controlled studies (RCTs)
but comprised two intervention groups, respectively, and were used as comparative
studies [38,39]. Five studies had a moderate risk of bias, whilst nine studies had a high risk of
bias (Supplementary Table S4). Interventions varied across the included studies (diet, diet + behavior
change program, diet + Metformin, diet + anti-obesity drug, anti-obesity drug, diet + anti-obesity
drug + exercise, bariatric surgery, and various exercise training programs), as did the duration of
interventions. Nine studies were designed with the specific aim of weight loss [34,37–39,41–43,45,46],
while the remaining five studies did not state if the aim was weight loss [30,31,33,40,44]. The sample
size of the studies varied from 31 to 1016.
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Age 27.5 ± 5.77
BMI 35.4 ± 5.31
ESHRE/ASRM
n = 29
Age 32.1 ± 5.64
BMI 36.4 ± 6.47
n = 18
Not reported Not reported Galactorrhea
Duration: 24 weeks
Normal protein diet, 600 kcal/day
energy deficit, Orlistat (Xenical®,
Roche) 120 mg × 3 times daily
Aim of weight loss: not stated
Anthropo-metric: BMI
Reproductive: T, SHBG
Metabolic: FG, 2HRG, FI
Moderate
Moran 2007 [34] Comparativestudy Australia
Age 31.7 ± 6.2
BMI 35.7 ± 5.8
ESHRE/ASRM
n = 15
Age 37.1 ± 4.7
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Diabetes, adrenal disorders, recent
weight change, regular physical
activity, pregnancy, breastfeeding,
smoking
Duration: 12 weeks supervised
intensified exercise training 60 min
three times weekly
Aim of weight loss: not stated
Anthropo-metric: WC,
Weight, BMI, VF, SCFAT
Reproductive: T, SHBG, FAI
Metabolic: FG, FI, lipids, BP
Moderate
Cheang 2016 [43] Comparativestudy USA
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Standardized hypocaloric diet (50%
carbohydrate, 20% protein, 30% fat)
with 500–1000 kcal/day deficit.
No modification of physical activity
or other weight loss methods.
Aim of weight loss: Yes
Anthropometric: Weight,
BMI Metabolic: FG, FI Moderate
Kogure 2016 [44] Comparativestudy Brazil
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Age 29.6 ± 5.2












Progressive resistance training (PRT)
for 1 h/day three times per week.
Aim of weight loss: not stated
Anthropometric: Weight,
BMI, WC, TFFM, % body fat
Reproductive: T, SHBG, FAI
Metabolic: FG, FI, HOMA-IR
Moderate
Villa 1999 [40] Comparativestudy Italy
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BMI 27.4 ± 6.8
n = 14
Not reported Not reported Not reported
Duration: 4–5 weeks
50 mg Naltrexone daily
Aim of weight loss: not stated
Anthropo-metric: BMI
Reproductive: T, SHBG, FAI
Metabolic: FG, FI
High
Kowalska 2001 [33] Comparativestudy Poland
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BMI 34.7 ± 6.0
NIH
n = 11
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Not reported No additional
Duration: 4–5 months
Hypocaloric diet (1200–1400
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Metabolic: FI
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diet (600 kcal/day energy deficit,
moderate intensity aerobic exercise,
1 h × 3 times/week, Orlistat 120 mg
before each meal)
Aim of weight loss: Yes
Anthropo-metric: WC, BMI
Reproductive: T, FAI, SHBG
Metabolic: FG, lipids
High
Kahal 2015 [41] Comparativestudy UK
Age 33.9 ± 6.7
BMI 37.9 ± 5.0
ESHRE/ASRM
n = 13
Age 33.5 ± 7.1






Alcohol intake >14 units/week
Non-PCOS: history of hirsutism or
menstrual irregularities
Duration: 6 months
Liraglutide 0.6 mg o.d subcutaneous
injection for 1 week, 1.2 mg o.d for 1
week, and 1.8 mg o.d thereafter for 6
months. No diet or exercise advice
given.
Aim of weight loss: Yes
Anthropometric: Weight,
BMI High
Nikokavora 2015 [42] Comparativestudy UK
Age 35.7 ± 8.9
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Type 1 diabetes, porphyria, lactose
intolerance, major cardio- or
cerebrovascular disease, history of
renal or hepatic disease, cancer,
epilepsy, major psychological or
eating disorders, breastfeeding,




program (LighterLife Total), 600 kcal
(36% protein, 36% carbohydrate, 28%
fat) as food packs alongside behavior
change program
Aim of weight loss: Yes
Anthropometric: Weight,
BMI High
Bhandari 2016 [45] Comparativestudy India
Age 27.8 ± 4.50
BMI 42.5 ± 5.71
ESHRE/ASRM
n = 43
Age 29.3 ± 4.96











complications intra or post
operatively
Duration: 6 months post-surgery
Sleeve gastrectomy (bariatric
surgery)






Al-Eisa 2017 [46] Comparativestudy Egypt
Age 27.9 ± 4.1
BMI 33.5 ± 2.75
ESHRE/ASRM
n = 30
Age 27.6 ± 5.7






Normal BMI, other diseases such
as diabetes or viral infections
Duration: 12 weeks
treadmill walking, 45 min three

























Diabetes, renal or liver dysfunction
Duration: 6 months
One month hypocaloric diet
(1200–1400 kcal daily), Metformin
850 mg twice daily.






Toscani 2011 [39] RCT Brazil









Not reported No hormonaldrugs pre study Diabetes, renal dysfunction
Duration: 2 months
Diet 1: HP (30% protein, 40%
carbohydrate, 30% fat)
Diet 2: NP (15% protein, 55%
carbohydrate, 30% fat)
Aim of weight loss: Yes
Anthropo-metric: Weight,
WC, BMI
Reproductive: T, SHBG, FAI
Metabolic: BP, FG, 2HRG, FI,
2HRI, lipids
High
2HRG: 2 h glucose; 2HRI: 2 h insulin; BMI, body mass index; BMR, basal metabolic rate; BP, blood pressure; FAI, free androgen index; FG, fasting glucose; FI, fasting insulin; IL-6,
interleukin-6; PCOS, polycystic ovary syndrome; SAT, subcutaneous abdominal tissue; SCFAT, subcutaneous fat; SHBG, sexual-hormone binding globulin; T, total testosterone; TFFM, total
fat free mass; TFM, total fat mass; TNF-α, tumor necrosis factor-α; VAT, visceral abdominal tissue; VF, visceral fat; WC, waist circumference.
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3.2. Outcomes: Anthropometric
3.2.1. Weight
Six studies including eight intervention groups reported weight as endpoint
data [31,38,39,42,45,46], whilst a further three studies reported change in weight [34,41,43],
and one study reported the estimated difference in weight from baseline to post-intervention [44]
(Table 2). Five of the studies reported that the difference in weight post-intervention or the change
in weight from baseline between the PCOS and non-PCOS groups was not statistically significantly
different, whilst the remainder of studies did not report a p-value.
3.2.2. Body Mass Index (BMI)
Thirteen intervention groups from 12 studies [30,31,33,36,38,40–46] reported BMI (Table 2).
One study reported a statistically significant difference in BMI following bariatric surgery (p = 0.013),
with women with PCOS having a lower BMI post-surgery than women without PCOS [45]. This study,
however, had a high risk of bias, with a number of key elements of the study protocol not reported
and should therefore be interpreted with caution. Three studies reported a non-statistically significant
difference in BMI between the two groups, whilst eight studies did not report a p-value.
3.2.3. Waist Circumference (WC)
Seven studies including nine intervention groups [31,33,37–39,44,46] reported WC (Table 2).
The majority of studies did not compare between-group differences after the interventions, with
only one study reporting a non-statistically significant difference in WC between groups following
progressive resistance training [44].
3.2.4. Body Composition
Three intervention groups from two studies [31,38] measured body composition with computed
tomography (CT). One study with an exercise intervention reported abdominal visceral fat (VF)
and subcutaneous fat (SCFAT). Two intervention groups from one study with the interventions
diet + Metformin and diet + placebo reported visceral adipose tissue area (VAT) and subcutaneous




One study with a diet intervention [34] reported double the number of ovulatory events in women
without PCOS compared to women with PCOS, which was statistically significant (Table 3).
3.4. Outcomes: Reproductive Non-Fertility
3.4.1. Total Testosterone
Eight intervention groups from seven studies reported total testosterone [30,31,33,35,38,40,44].
One study with a hypocaloric diet + an anti-obesity drug intervention (Orlistat) [30], and another
study with an anti-obesity drug intervention (Orlistat) + a hypocaloric diet + exercise intervention [35]
reported a statistically significant difference in total testosterone following intervention between the
two study groups, with the non-PCOS group having lower values in both studies (Table 3). However,
as expected in both studies, the women with PCOS had statistically significantly higher levels of
testosterone at baseline than women without PCOS.
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Table 2. Anthropometric outcomes.
Outcome Reference Intervention Baseline PCOS:Mean± SD
Baseline Non-PCOS:




Non-PCOS: Mean± SD p-Value *
Weight (kg)
Pasquali 2000 [38] Hypocaloric diet 102 ± 19 106 ± 13 NR 97 ± 18 100 ± 13 NR
Cheang 2016 [43] Hypocaloric diet 99.2 ± 13.3 97.6 ± 15.4 0.7508 −4.08 ± 3.65 −4.69 ± 2.98 0.6281
Moran 2007 [34] Hypocaloric diet 95.1 ± 19.3 95.5 ± 16.5 NS −3.9 ± 3.6 −4.5 ± 4.1 0.642
Toscani 2011 [39] High protein diet 74.62 ± 18.8 75.89 ± 13.49 NR 71.4 ± 15.45 74.54 ± 13.71 NR
Toscani 2011 [39] Normal protein diet 82.85 ± 15.18 77.51 ± 13.31 NR 79.82 ± 16.51 74.31 ± 13.88 NR
Nikokavoura 2015 [42] VLCD + behaviour change 108.3 ± 18.1 107.4 ± 19.8 0.713 89.8 ± 16.7 88.0 ± 17.6 0.19
Pasquali 2000 [38] Hypocaloric diet + Metformin 103 ± 18 101 ± 8 NR 94 ± 17 88 ± 7 NR
Kahal 2015 [41] AO drug (Liraglutide) 102.1 ± 17.1 100.4 ± 15.1 NS −3.0 ± 4.2 −3.8 ± 3.4 0.56
Bhandari 2016 [45] Bariatric surgery 106.89 ± 17.79 117.03 ± 19.89 NR 77.27 ± 10.72 84.89 ± 13.18 NR
Hutchison 2011 [31] Intensified exercise training 100.5 ± 4.5 ! 96.2 ± 3.5 ! 0.42 95.3 ± 4.8 ! 96.9 ± 4.5 ! NR
Kogure 2016 [44] Progressive resistance training 73.1 ± 15.6 68.1 ± 15.4 NS 0.52 [−0.31, 1.36] ˆ 0.13 [−0.64, 0.90] ˆ 0.14
Al−Eisa 2017 [46] Aerobic training 89.8 ± 6.95 84.9 ± 7.2 NR 84.8 ± 6.42 82.2 ± 5.72 NR
BMI (kg/m2)
Pasquali 2000 [38] Hypocaloric diet 39.6 ± 6.9 40.1 ± 6.2 NR 38 ± 6.2 37.8 ± 5.7 NR
Cheang 2016 [43] Hypocaloric diet 36.6 ± 5.1 35.8 ± 4.8 0.6507 −1.46 [−0.72, −2.20] # −1.80 [−1.14, −2.45] # 0.4829
Nikokavoura 2015 [42] VLCD + behaviour change 40.0 ± 6.3 40.0 ± 6.3 0.955 33.2 ± 6.0 32.8 ± 5.7 NR
Kowalska 2001 [33] Hypocaloric diet + Metformin 34.7 ± 6.0 36.2 ± 6.0 NS 31.4 ± 4.8 35.8 ± 7.9 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 39.8 ± 7.9 37.4 ± 3.0 NR 36.4 ± 7.4 32.9 ± 3.4 NR
Diamanti−Kandarakis 2007 [30] Hypocaloric diet + AO drug (Orlistat) 35·43 ± 5·31 36·39 ± 6·47 0.58 29.7 ± 4.57 30.15 ± 4.13 NR
Vosnakis 2013 [36] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 34.83 ± 6.39 36.79 ± 6.98 NR 30.21 ± 5.78 31.01 ± 4.93 NR
Kahal 2015 [41] AO drug (Liraglutide) 37.9 ± 5.0 36.5 ± 4.6 NS −1.0 ± 1.5 −1.4 ± 1.2 0.43
Villa 1999 [40] AO drug (Naltrexone) 27.5 ± 6.8 27.4 ± 6.8 NS 26.8 ± 6.7 27 ± 6.8 NR
Bhandari 2016 [45] Bariatric surgery 42.52 ± 5.66 45.03 ± 6.3 0.0717 30.76 ± 2.93 32.67 ± 3.51 0.013
Hutchison 2001 [31] Intensified exercise training 37.4 ± 1.5 ! 35.7 ± 1.3 ! 0.43 35 ± 1.6 ! 35.9 ± 1.8 ! NR
Kogure 2016 [44] Progressive resistance training 28.4 ± 6.0 26.2 ± 5.7 NS 0.21 [−0.11, 0.54] ˆ 0.05 [−0.25, 0.35] ˆ 0.08
Al−Eisa 2017 [46] Aerobic training 33.45 ± 2.75 31.7 ± 3.8 NR 28.5 ± 2.25 26.8 ± 2.54 NR
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Table 2. Anthropometric outcomes.
Outcome Reference Intervention Baseline PCOS:Mean± SD
Baseline Non-PCOS:




Non-PCOS: Mean± SD p-Value *
WC (cm)
Pasquali 2000 [38] Hypocaloric diet 109 ± 19 109 ± 11 NR 104 ± 13 105 ± 12 NR
Toscani 2011 [39] High protein diet 87.74 ± 14.08 83.92 ± 9.13 <0.05 86 ± 12.92 81.83 ± 9.13 NR
Toscani 2011 [39] Normal protein diet 93.32 ± 8.05 84.02 ± 9.03 <0.05 90.03 ± 10.41 81.7 ± 11.72 NR
Kowalska 2001 [33] Hypocaloric diet + Metformin 98.1 ± 14.8 102.3 ± 13.0 NS 93.4 ± 11.8 100 ± 19.5 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 107 ± 16 102 ± 6 NR 100 ± 15 94 ± 6 NR
Panidis 2008 [37] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 101.52 ± 2.67 100.53 ± 3.94 NS 87.86 ± 2.29 87.67 ± 2.82 NR
Hutchison 2011 [31] Intensified exercise training 106.8 ± 3.4 ! 102.8 ± 2.6 ! 0.39 103.1 ± 4 ! 99.9 ± 4.1 ! NR
Kogure 2016 [44] Progressive resistance training 81.7 ± 12.8 76.2 ± 11.3 <0.05 0.86 [0.32, 1.40] ˆ 0.27 [−0.21, 0.75] 0.21
Al−Eisa 2017 [46] Aerobic training 96.2 ± 3.52 94.2 ± 3.82 NR 93.8 ± 3.26 72.7 ± 2.6 NR
VAT/VF (cm2)
Pasquali 2000 [38] Hypocaloric diet 121 ± 48 181 ± 94 NR 108 ± 36 159 ± 83 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 151 ± 91 133 ± 38 NR 113 ± 59 100 ± 37 NR
Hutchison 2011 [31] Intensified exercise training 129.2 ± 12.8 ! 121.5 ± 9.4 ! 0.65 107.6 ± 15.1 ! 132.7 ± 18.1 ! NR
SAT/SCFAT
(cm2)
Pasquali 2000 [38] Hypocaloric diet 589 ± 127 554 ± 118 NR 574 ± 111 508 ± 107 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 535 ± 147 554 ± 79 NR 485 ± 170 462 ± 81 NR
Hutchison 2011 [31] Intensified exercise training 590.2 ± 35.2 ! 550.3 ± 45.2 ! 0.49 538.4 ± 40.2 ! 558.5 ± 74.5 ! NR
* Between-group difference; ! mean ± SEM; ˆ estimated difference [95% confidence interval]; # mean [95% confidence interval]; AO, anti-obesity; BMI, body mass index; NR, not reported;
NS, not significant; PCOS, polycystic ovary syndrome; SAT, subcutaneous adipose tissue area; SCFAT, subcutaneous fat; VAT, visceral adipose tissue area; VF, visceral fat; VLCD, very low
calorie diet; WC, waist circumference.
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3.4.2. Sex Hormone-Binding Globulin (SHBG)
Eight intervention groups from seven studies reported SHBG [30,31,33,35,38,40,44], with the
majority of studies not reporting whether there were between-group statistical significance (Table 3).
One study with a hypocaloric diet + anti-obesity drug (Orlistat) intervention [30] reported a statistically
significant difference between groups (p < 0.05) following the intervention; however, there was also a
statistically significant difference in SHBG at baseline between the groups (p < 0.05).
3.4.3. Free Androgen Index (FAI)
Five studies reported FAI [31,33,35,40,44], with one study with an anti-obesity drug intervention
(Orlistat) + a hypocaloric diet + exercise intervention [35] reporting a statistically significant difference
in values post intervention between groups (p = 0.021), with women in the non-PCOS group having
a lower mean value (Table 3). However, as expected, women with PCOS in this study had a higher
mean FAI at baseline (p < 0.001).
3.5. Outcomes: Metabolic
3.5.1. Fasting Glucose
Eleven intervention groups from nine studies reported fasting glucose [30,31,35,38–40,43,44,46].
The majority of studies did not report whether there were between-group statistical significance, and
three studies [35,43,44] reported that there was no statistically significant difference in fasting glucose
post-intervention between the two groups (Table 4).
3.5.2. Oral Glucose Tolerance Test (OGTT-Glucose)
Three intervention groups from two studies reported OGTT-glucose [30,39]. None of these
studies reported whether there were between-group statistical significance following the interventions
(Table 4).
3.5.3. Fasting Insulin
Eleven intervention groups from nine studies reported fasting insulin [30,31,33,35,38–40,44,46].
Only one of these studies reported a p-value for the between-group difference following the
interventions (p = 0.58) [44] (Table 4).
3.5.4. Lipids
Four intervention groups from three studies reported results for blood lipids [31,35,39]. One
study with an anti-obesity drug intervention (Orlistat) + a hypocaloric diet + exercise intervention [35]
reported a statistically significant difference in total, LDL and HDL cholesterol post-intervention
between groups, with women in the PCOS group having lower mean values (Table 5).
3.5.5. Blood Pressure (BP)
Three intervention groups from two studies reported results for BP [32,39]. None of the studies
reported whether there were between-group statistical significance (Table 5).
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Table 3. Reproductive outcomes.

















Pasquali 2000 [38] Hypocaloric diet 1.77 ± 0.59 1.32 ± 0.42 <0.05 1.63 ± 0.45 1.14 ± 0.35 NR
Kowalska 2001 [33] Hypocaloric diet + Metformin 3.57 ± 1.01 1.91 ± 0.42 <0.05 2.39 ± 1.11 1.7 ± 0.59 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 2.36 ± 1.21 1.46 ± 0.38 <0.01 1.7 ± 0.87 1.25 ± 0.38 NR
Diamanti-Kandarakis
2007 [30] Hypocaloric diet + AO drug (Orlistat) 3.01 ± 0.94 1.50 ± 0.43 <0.001 2.28 ± 0.65 1.49 ± 0.36 <0.05
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 2.56 ± 1.00 1.33 ± 0.45 <0.001 2.1 ± 0.78 1.41 ± 0.74 0.006
Villa 1999 [40] AO drug (Naltrexone) 1.7 ± 0.5 1.4 ± 0.5 NS 1.9 ± 1.76 1.5 ± 1.2 NR
Hutchison 2011 [31] Intensified exercise training 2.9 ± 0.2! 1.6 ± 0.2 ! <0.01 2.8 ± 0.3 ! 1.8 ± 0.3 ! NR
Kogure 2016 [44] Progressive resistance training 3.12 ± 1.22 2.58 ± 1.02 <0.05 0.59 [0.30, 0.89] ˆ 0.42 [0.16, 0.68] ˆ 0.15 #
SHBG (nmol/L)
Pasquali 2000 [38] Hypocaloric diet 16.0 ± 7.04 20.2 ± 10.7 NS 13.8 ± 2.1 28.1 ± 14.7 NR
Kowalska 2001 [33] Hypocaloric diet + Metformin 32.0 ± 18.3 32.5 ± 16.5 NS 38.6 ± 19.3 36.5 ± 13.3 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 18.7 ± 15.0 23.4 ± 22.7 NS 16.7 ± 8.1 28.9 ± 16.5 NR
Diamanti-Kandarakis
2007 [30] Hypocaloric diet + AO drug (Orlistat) 28.72 ± 12.48 40.92 ± 19.54 0.01 37.21 ± 17.59 58.6 ± 27.02 <0.05
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 30.3 ± 13.2 47.8 ± 34.7 0.012 40.3 ± 20.4 62.2 ± 35.5 NS
Villa 1999 [40] AO drug (Naltrexone) 30.2 ± 20.4 38.2 ± 16.4 NS 32.5 ± 20.9 39.2 ± 15.7 NR
Hutchison 2011 [31] Intensified exercise training 29.0 ± 1.8! 43.6 ± 7.8 ! 0.04 30.7 ± 2.8 ! 54.3 ± 10.6 ! NR
Kogure 2016 [44] Progressive resistance training 54.9 ± 37.8 63.0 ± 35.7 NS 0.12 [0.02, 0.23] ˆ 0.09 [−0.01, 0.18] ˆ 0.37 #
FAI
Kowalska 2001 [33] Hypocaloric diet + Metformin 14.49 ± 8.49 9.97 ± 7.95 <0.05 9.31 ± 9.95 5.49 ± 3.9 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 10.25 ± 6.31 3_71 ± 2.11 <0.001 6.76 ± 4.32 2.71 ± 1.74 0.021
Villa 1999 [40] AO drug (Naltrexone) 9.3 ± 6.5 4.9 ± 3.1 <0.05 8.9 ± 5.7 5.2 ± 3.3 NR
Hutchison 2011 [31] Intensified exercise training 10.7 ± 1.1 ! 4.6 ± 0.9 ! <0.01 10.1 ± 1.6 ! 4.1 ± 1.1 ! NR
Kogure 2016 [44] Progressive resistance training 8.3 ± 6.3 5.6 ± 4.6 <0.05 0.98 [−0.03,1.99] ˆ 0.37 [−0.50, 1.24] ˆ 0.25
#
* Between-group difference; ! mean ± SEM; ˆ estimated difference [95% confidence interval]; # p value adjusted for age, BMI, and HOMA-IR; AO, anti-obesity; FAI, free androgen index;
NR, not reported; NS, not significant; PCOS, polycystic ovary syndrome; SHBG, sex hormone-binding globulin.
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Table 4. Glucose and insulin homeostasis.
Outcome References Intervention Baseline PCOS:Mean± SD
Baseline Non-PCOS:









Pasquali 2000 [38] Hypocaloric diet 5.61 ± 1.0 5.11 ± 0.56 NS 5.27 ± 0.61 5.16 ± 0.94 NR
Cheang 2016 [43] Hypocaloric diet 4.75 ± 0.45 4.67 ± 0.21 0.60 −0.06 (−0.25, 0.12) % 0.01 (−0.13, 0.15) % 0.5041
Toscani 2011 [39] High protein diet 4.97 ± 0.34 4.95 ± 0.45 NS 5.02 ± 0.40 5.05 ± 0.54 NR
Toscani 2011 [39] Normal protein diet 4.90 ± 0.36 4.98 ± 0.41 NS 4.98 ± 0.35 5.02 ± 0.35 NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 5.49 ± 1.61 4.94 ± 0.56 NS 5 ± 0.94 4.94 ± 0.72 NR
Diamanti-Kandarakis
2007 [30] Hypocaloric diet + AO drug (Orlistat) 5.72 ± 0.51 5.77 ± 0.61 0.92 5.52 ± 0.47 5.69 ± 0.52 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 5.58 ± 0.57 5.81 ± 0.66 NS 5.28 ± 0.56 5.58 ± 0.51 NS
Villa 1999 [40] AO drug (Naltrexone) 4.65 ± 0.33 4.55 ± 0.22 NS 4.33 ± 0.56 4.48 ± 0.37 NR
Hutchison 2011 [31] Intensified exercise training 5.0 ± 0.1 ! 4.8 ± 0.1 ! 0.57 4.9 ± 0.1 ! 4.9 ± 0.1 ! NR
Kogure 2016 [44] Progressive resistance training 5.34 ± 0.91 5.31 ± 0.97 NS 0.37 [0.08, 0.66] $ 0.30 [0.04, 0.56] $ 0.12 **
Al-Eisa 2017 [46] Aerobic training 4.50 ± 2.80 5.59 ± 1.57 NR 4.50 ± 2.80 5.59 ± 1.57 NR
OGTT-glucose
(mmol/L)
Toscani 2011 [39] High protein diet 6.27 ± 1.60 5.02 ± 0.99 NR 6.92 ± 2.0 5.63 ± 1.56 NR
Toscani 2011 [39] Normal protein diet 6.55 ± 1.50 5.41 ± 1.02 NR 6.64 ± 2.16 5.18 ± 1.02 NR
Diamanti-Kandarakis
2007 [30] Hypocaloric diet + AO drug (Orlistat) 6.35 ± 1.35 6.54 ± 1.54 0.65 6.17 ± 0.85 6.21 ± 1.77 NR
Fasting insulin
(pmol/L)
Pasquali 2000 [38] Hypocaloric diet 240.36 ± 214.53 149.24 ± 79.64 NS 136.33 ± 103.32 103.32 ± 76.06 NR
Toscani 2011 [39] High protein diet 76.05 (60.00–123.41) ˆ 57.85 (28.20–84.94) ˆ <0.05 61.67 (52.71–108.83) ˆ 56.74 (33.20–97.92) ˆ NR
Toscani 2011 [39] Normal protein diet 128.83 (93.06–213.28) ˆ 59.59 (41.04–84.52) ˆ <0.05 129.15 (76.99–233.04) ˆ 48.00 (31.14–80.14) ˆ NR
Pasquali 2000 [38] Hypocaloric diet + Metformin 308.53 ± 218.12 217.40 ± 58.84 NS 154.98 ± 223.86 102.6 ± 60.99 NR
Kowalska 2001 [33] Hypocaloric diet + Metformin 26.2 ± 13.9 # 18.3 ± 14.2 # <0.05 16.9 ± 9.1 # 20.0 ± 13.5 # NR
Diamanti-Kandarakis
2007 [30] Hypocaloric diet + AO drug (Orlistat) 127.37 ± 61.12 125.5 ± 87.09 0.45 76.4 ± 34.93 77.02 ± 47.3 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 129.87 ± 75.01 133.34 ± 161.82 NS 81.08 ± 50.94 68.16 ± 40.18 NS
Villa 1999 [40] AO drug (Naltrexone) 99.7 ± 75 104.3 ± 63.1 NS 90.4 ± 61 85.3 ± 39.4 NR
Hutchison 2011 [31] Intensified exercise training 141.6 (100.8–181.2) ˆ 72.6 (58.8–115.8) ˆ 0.02 97.8 (66.6–231.0) ˆ 115.2 (76.2–177.6) ˆ NR
Kogure 2016 [44] Progressive resistance training 64.59 ± 47.92 36.11 ± 31.25 <0.05 0.90 [−0.21, 1.94] $ −0.90 [−1.88, 0.07] $ 0.58 **
Al-Eisa 2017 [46] Aerobic training 17.8 ± 4.20 @ 20.6 ± 8.2 @ NR 14.8 ± 2.9 @ 16.1 ± 5.1 @ NR
* Between-group difference; ! mean ± SEM; ˆ median (IQ range); # IU/L; @ data reported as mU/mL (as per original study); % mean (95% confidence interval); $ estimated difference
[95% confidence interval]; ** p value adjusted for age, BMI, and HOMA-IR; AO, anti-obesity; f-glucose, fasting glucose; f-insulin, fasting insulin; NR, not reported; NS, not significant;
OGTT-glucose, oral glucose tolerance test glucose; PCOS, polycystic ovary syndrome.
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Table 5. Lipids and blood pressure.















Toscani 2011 [39] High protein diet 4.60 ± 1.15 4.24 ± 0.71 NR 4.32 ± 1.12 4.19 ± 0.82 NR
Toscani 2011 [39] Normal protein diet 4.31 ± 1.04 4.05 ± 1.13 NR 4.02 ± 0.82 3.86 ± 1.36 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 5.04 ± 1.00 5.48 ± 0.93 NS 4.52 ± 0.82 4.55 ± 0.87 <0.001




Toscani 2011 [39] High protein diet 3.91 ± 1.09 3.66 ± 0.61 NR 3.78 ± 1.1 3.54 ± 0.76 NR
Toscani 2011 [39] Normal protein diet 3.62 ± 0.95 3.30 ± 1.11 NR 3.33 ± 0.75 3.13 ± 1.34 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 3.30 ± 0.90 3.65 ± 0.68 NS 2.87 ± 0.84 2.98 ± 0.47 0.001




Toscani 2011 [39] High protein diet 1.30 ± 0.19 1.35 ± 0.38 NR 1.27 ± 0.2 1.34 ± 0.39 NR
Toscani 2011 [39] Normal protein diet 1.19 ± 0.32 1.39 ± 0.26 NR 1.18 ± 0.32 1.5 ± 0.25 NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic exercise 1.20 ± 0.22 1.32 ± 0.31 NS 1.21 ± 0.23 1.21 ± 0.26 0.006
Hutchison 2011 [31] Intensified exercise training 1.0 ± 0.1 ! 1.2 ± 0.1 ! 0.04 1 ± 0.1 ! 1.2 ± 0.1 ! NR
Triglycerides
(mmol/L)
Toscani 2011 [39] High protein diet 0.86 (0.47–1.47) ˆ 0.68 (0.47–0.76) ˆ NR 0.55 (0.49–0.71) ˆ 0.92 (0.55–1.02) ˆ NR
Toscani 2011 [39] Normal protein diet 0.97 (0.67–1.30) ˆ 0.71 (0.41–1.62) ˆ NR 0.94 (0.81–1.15) ˆ 0.88 (0.64–1.21) ˆ NR
Panidis 2014 [35] Hypocaloric diet + AO drug (Orlistat) +moderate intensity aerobic training 1.17 ± 0.56 1.28 ± 0.62 NS 0.99 ± 0.44 0.87 ± 0.25 NS
Hutchison 2011 [31] Intensified exercise training 1.4 ± 0.2 ! 1.2 ± 0.2 ! 0.46 0.9 ± 0.1 ! 1.3 ± 0.1 ! NR
BP systolic
(mmHg)
Toscani 2011 [39] High protein diet 125.7 ± 19.0 116.1 ± 10.41 NR 126 ± 23.1 117.85 ± 10.18 NR
Toscani 2011 [39] Normal protein diet 119.1 ± 16.4 116.43 ± 10.3 NR 119.36 ± 15.38 110.71 ± 7.32 NR
Harrison 2012 [32] Intensified exercise training 108 ± 14.6 ! 118 ± 16.7 ! NS 109 ± 10.4 ! 116 ± 16.2 ! NR
BP diastolic
(mmHg)
Toscani 2011 [39] High protein diet 77.9 ± 10.75 74.6 ± 8.46 NR 80 ± 11.2 74 ± 8.83 NR
Toscani 2011 [39] Normal protein diet 78 ± 11.83 75.14 ± 9.6 NR 77.82 ± 12.02 72.57 ± 7.72 NR
Harrison 2012 [32] Intensified exercise training 72 ± 10.2 ! 75 ± 8.8 ! NS 69 ± 7.4 ! 73 ± 10.5 ! NR
* Between-group difference; ! mean ± SEM; ˆ median (IQ range); AO, anti-obesity; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NR, not reported;
NS, not significant; PCOS, polycystic ovary syndrome.
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4. Discussion
In this systematic review, we evaluated for the first time the effect of weight management
interventions in women with PCOS compared to women without PCOS. We identified 14 studies in
933 women with considerable clinical heterogeneity across a range of lifestyle (dietary and non-dietary)
and non-lifestyle weight management interventions including diet, diet + behavior change program,
diet + Metformin, diet + anti-obesity drug, anti-obesity drug, diet + anti-obesity drug + exercise,
bariatric surgery, and various exercise training programs. Overall, there were no statistically significant
differences in weight at the end of an intervention or in change in weight, between groups for five of
the interventions included, with the remainder of studies not reporting whether there was a difference
between groups post-intervention. For the majority of secondary endpoints, there was little difference
between groups. Furthermore, five of the included studies had a moderate risk of bias, whilst nine
studies had a high risk of bias.
The included studies are set in a research environment, with structured interventions, isocaloric
intake and frequent contact and interaction with trained professionals. This mirrors many structured
lifestyle interventions, and like all research in lifestyle interventions, occurred in a motivated
research population.
As with all lifestyle intervention studies, our results may not reflect the outcomes of
community-based studies or self-induced lifestyle change. Our previous research has shown a
greater 10-year weight gain (2.6 kg (95% CI: 1.2–4.0)) in community-based cohort studies [17], and an
elevated prevalence of overweight (risk ratio (RR) (95% CI): 1.95 (1.52, 2.50)), obesity (2.77 (1.88, 4.10)),
central obesity (1.73 (1.31, 2.30)) and BMI (2.5 kg/m2 (95% CI: 1.9–3.1)) in systematic reviews [15]
of women with PCOS compared to women without PCOS. This may relate to hyperinsulinemia,
reduced postprandial thermogenesis [27], altered metabolic rate [47], impaired regulation of gut
hormones or appetite regulation or limited self-regulation of food intake [48–50]. While the evidence
here is not reliable enough to state conclusively if there is no difference in the effect of weight
management interventions in women with and without PCOS, if this was indeed the case, this
could indicate that appetite and self-regulation may be more prominent contributors to weight in
PCOS. These mechanisms are more likely to selectively manifest in a free-living environment with ad
libitum food intake. Our past longitudinal community cohort studies also show unselected community
dwelling women with PCOS report a higher caloric intake, which corresponds closely to higher rates
of weight gain [51]. More research into appetite and self-regulation around food intake are needed
in PCOS.
The majority of secondary endpoints were similar between women with and without PCOS
following the specified interventions. Similar to weight, a large number of the included studies did not
report whether there was a statistically significant difference between groups for secondary endpoints
following the intervention. While for a limited number of outcomes, there was a statistically significant
difference in these measures at study completion, this difference was also present at baseline indicating
that examining the within-group change from baseline to the end of the intervention would be more
appropriate. We also report changes in secondary outcomes including total testosterone and SHBG at
study completion between women with and without PCOS. However, women with PCOS generally
have hyperandrogenism and lower SHBG [52] and differences at the end of the intervention are again
likely related to baseline differences.
Here, it was not possible to determine the relative effectiveness of specific dietary or non-dietary
interventions. Based on our findings reported elsewhere [21,22], recommendations in PCOS for
lifestyle or pharmacological intervention and weight management should mirror those for the
general population. These include a diet with reduced energy intake and a weight loss maintenance
program for maintaining weight. Pharmacological treatment can increase efficacy of lifestyle
interventions [53,54]. A recent meta-analysis reported that a metformin plus lifestyle intervention
results in more reduction in fat and improved menstrual cyclicity, compared to lifestyle alone in
PCOS [53]. In general populations, a large meta-analysis (n = 80 studies, n = 26,455 participants)
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reported that diet interventions in isolation are as effective for short-term (six months) weight
loss compared to anti-obesity drugs. Long-term (24 months) weight-loss, however, was greater
with anti-obesity drugs [55]. Overall, bariatric surgery is an option for those who have not
responded to these interventions with sufficient weight loss or for those with morbid obesity and
co-morbidities [56,57]. Overall, the relative efficacy of different weight management interventions in
women with and without PCOS warrants further investigation.
The strengths of this study include the comprehensive range of lifestyle and weight management
interventions and of obesity-related outcomes studied. We also included studies where weight loss
was not the specific goal, broadening applicability of our findings to weight gain prevention, weight
maintenance and use in lean women with PCOS. The weaknesses of this review include the inability
to statistically combine study results due to clinical heterogeneity. Additionally, this systematic review
was limited to studies in English. Many of the included studies did not report numeric differences
between groups and relevant data could not be extracted. The identified studies also had moderate to
high risk of bias and were generally small with significant drop-outs. Many did not strictly exclude
PCOS status in their controls. Future research should address these methodological weaknesses to
improve study quality. We also did not prospectively register this review on PROSPERO; however, it
was designed in 2012 at which time PROSPERO had only been active for a relatively short amount
of time, and it was not yet standard practice for all systematic reviews to be prospectively registered.
Additional biases may also have occurred through identifying articles only in English and through not
contacting authors for missing data. Detailed reporting of inclusion and exclusion criteria, increased
participant numbers, attrition rates, anthropometric measurement protocols, and publishing study
protocols are suggested to improve the reliability and validity of future research. Endpoint reporting
could also be improved across the range of obesity-related health implications in PCOS, and through
the use of a pre-specified list of outcomes similar to that suggested for infertility treatment [58].
5. Conclusions
We report on the first systematic review comparing the effectiveness of weight management
strategies in women with and without PCOS. Our findings are that there is insufficient evidence to
indicate significant differences in weight loss in women with PCOS compared to women without
PCOS with lifestyle or weight management strategies. We cannot determine the relative efficacy of
different types of weight management interventions and note considerable limitations with the current
studies. Further research with larger samples is warranted in controlled clinical trials and free-living
environments assessing a full range of defined PCOS and obesity-related health implications. At the
current time, recommendations for weight management for the general population should be applied
for women with PCOS with some degree of confidence that similar efficacy of structured interventions
is likely.
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